At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ARVN Arvinas Holding Company LLC
Trading 08-03 14:16:07 EDT
7.99
-0.04
-0.50%
High8.10Low7.92Vol300.33K
Open8.10D1 Closing8.03Amplitude2.24%
Mkt Cap513.15MTradable Cap445.88MTotal Shares64.22M
T/O2.40MT/O Rate0.54%Tradable Shares55.80M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Arvinas Shareholders Elect Two Directors at Annual Meeting
Reuters  ·  06-26
Arvinas Shareholders Elect Two Directors at Annual Meeting
Arvinas CMO Noah Berkowitz to depart July 3, company starts search for successor
Reuters  ·  06-23
Arvinas CMO Noah Berkowitz to depart July 3, company starts search for successor
Rigel Pharmaceuticals pays $70 million upfront for global rights to Arvinas-Pfizer breast cancer drug VEPPANU
Reuters  ·  06-18
Rigel Pharmaceuticals pays $70 million upfront for global rights to Arvinas-Pfizer breast cancer drug VEPPANU
Rigel Deal for VEPPANU Cleared, Arvinas Receives Payment
TIPRANKS  ·  06-17
Rigel Deal for VEPPANU Cleared, Arvinas Receives Payment
BRIEF-Arvinas - Pfizer, And Rigel Receive Hart-Scott-Rodino Clearance For License Agreement On June 11, 2026
Reuters  ·  06-17
BRIEF-Arvinas - Pfizer, And Rigel Receive Hart-Scott-Rodino Clearance For License Agreement On June 11, 2026
Arvinas - Pfizer, and Rigel Receive Hsr Clearance for License Agreement on June 11, 2026 - SEC Filing
THOMSON REUTERS  ·  06-17
Arvinas - Pfizer, and Rigel Receive Hsr Clearance for License Agreement on June 11, 2026 - SEC Filing
Arvinas - Co and Pfizer Eligible for up to $320 Mln in Milestone Payments and Tiered Royalties - SEC Filing
THOMSON REUTERS  ·  06-17
Arvinas - Co and Pfizer Eligible for up to $320 Mln in Milestone Payments and Tiered Royalties - SEC Filing
Rigel closes VEPPANU license deal, makes USD 70 million upfront payment
Reuters  ·  06-17
Rigel closes VEPPANU license deal, makes USD 70 million upfront payment
Arvinas joins MJFF-backed PPMI study to support development of LRRK2 degrader ARV-102 for Parkinson’s
Reuters  ·  06-04
Arvinas joins MJFF-backed PPMI study to support development of LRRK2 degrader ARV-102 for Parkinson’s
Arvinas Joins the Michael J. Fox Foundation’s Lite and Ppmi Programs to Advance New Therapies Targeting Lrrk2 for Parkinson’s Disease
THOMSON REUTERS  ·  06-04
Arvinas Joins the Michael J. Fox Foundation’s Lite and Ppmi Programs to Advance New Therapies Targeting Lrrk2 for Parkinson’s Disease
Arvinas Price Target Maintained With a $18.00/Share by Stephens & Co.
Dow Jones  ·  06-03
Arvinas Price Target Maintained With a $18.00/Share by Stephens & Co.
Analysts Conflicted on These Healthcare Names: Arvinas Holding Company (ARVN), Lyell Immunopharma (LYEL) and Relay Therapeutics (RLAY)
TIPRANKS  ·  06-03
Analysts Conflicted on These Healthcare Names: Arvinas Holding Company (ARVN), Lyell Immunopharma (LYEL) and Relay Therapeutics (RLAY)
Arvinas Holding Company (ARVN) Gets a Buy from Barclays
TIPRANKS  ·  06-03
Arvinas Holding Company (ARVN) Gets a Buy from Barclays
Arvinas - Expects Cash Position as of March 31, 2026 to Fund Operations Into Second Half of 2028 - SEC Filing
THOMSON REUTERS  ·  06-03
Arvinas - Expects Cash Position as of March 31, 2026 to Fund Operations Into Second Half of 2028 - SEC Filing
Arvinas - Plans to Seek Out-Licensing Agreement for Additional Clinical Trials of Arv-806 - SEC Filing
THOMSON REUTERS  ·  06-03
Arvinas - Plans to Seek Out-Licensing Agreement for Additional Clinical Trials of Arv-806 - SEC Filing
Arvinas - Announces Re-Prioritization of Portfolio Following Strategic Review - SEC Filing
THOMSON REUTERS  ·  06-03
Arvinas - Announces Re-Prioritization of Portfolio Following Strategic Review - SEC Filing
Arvinas - Plans to Complete Phase 1 Monotherapy Dose Escalation Trial and Share Data in 2026 - SEC Filing
THOMSON REUTERS  ·  06-03
Arvinas - Plans to Complete Phase 1 Monotherapy Dose Escalation Trial and Share Data in 2026 - SEC Filing
Arvinas to present at Jefferies Global Healthcare Conference fireside chat
Reuters  ·  05-30
Arvinas to present at Jefferies Global Healthcare Conference fireside chat
Analysts Offer Insights on Healthcare Companies: Coya Therapeutics, Inc. (COYA), Beta Bionics, Inc. (BBNX) and Arvinas Holding Company (ARVN)
TIPRANKS  ·  05-22
Analysts Offer Insights on Healthcare Companies: Coya Therapeutics, Inc. (COYA), Beta Bionics, Inc. (BBNX) and Arvinas Holding Company (ARVN)
Wells Fargo Remains a Buy on Arvinas Holding Company (ARVN)
TIPRANKS  ·  05-22
Wells Fargo Remains a Buy on Arvinas Holding Company (ARVN)

Introduction

Company Name.
Arvinas Holding Company LLC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Issue price:
--